Status
Conditions
Treatments
About
Pleural effusion is characterized by the accumulation of fluid in the pleural space, which typically contains about 10-20 mL of pleural fluid that is crucial for the movement of the lungs against the chest wall. This fluid closely resembles plasma but has a lower protein concentration, usually less than 1.5 gm/dL. It primarily originates from pleural capillaries and the interstitial spaces of the lung, and is reabsorbed through the lymphatic vessels in the parietal pleura, either via small openings known as stomas or through a process called transcytosis (1, 2). When the balance between fluid production and reabsorption is disrupted-often due to various pathogenic mechanisms-it can lead to pleural effusion. In such cases, effective management is essential. This study aims to conduct a thorough comparison of the two talc administration methods-TS and TI-using sterilized, large-particle, asbestos-free talc powder. By examining key outcome measures such as pleurodesis success rates, procedural morbidity, and length of hospital stay, the goal is to provide clinicians with evidence-based guidance to facilitate informed decision-making in the management of pleural effusions.
Full description
One of the most effective interventions for managing malignant pleural effusion (MPE) and pneumothoraces is chemical pleurodesis, which involves the introduction of a sclerosing agent into the pleural space to induce inflammation and subsequent fibrosis, thereby closing the pleural space. Among the various agents used, talc is the most widely recognized for its high success rates, affordability, and availability (3-8). There are primarily two methods of delivering talc: talc slurry (TS), which involves injecting a talc suspension via a chest tube, and talc insufflation (TI), which is performed during thoracoscopic surgery. Currently, there is no consensus on which method is superior, leading to a recommendation for individualized patient approaches that consider the specific clinical scenario and aim to minimize complications while reducing hospital stays9 .
The choice of talc particle size is critical, as it has significant implications for both the efficacy of pleurodesis and the safety of the procedure. Historically, small-particle talc formulations (less than 10 μm) have been associated with severe complications such as acute respiratory distress syndrome (ARDS) 10. This has prompted a shift toward using larger particles (greater than 15 μm), which have been shown to decrease the risk of ARDS and other respiratory complications. Importantly, studies have demonstrated that the effectiveness of pleurodesis is not compromised by the use of larger particles11.Furthermore, recommendations now advocate for the use of a minimum effective dose of talc, typically around 4-5 grams, to optimize both efficacy and safety.
Another significant advancement in the use of talc for pleurodesis is the transition to asbestos-free formulations. Historically, some talc preparations contained trace amounts of asbestos, a known carcinogen linked to serious health risks such as mesothelioma. The move toward asbestos-free talc has been driven by the need to eliminate these long-term carcinogenic risks, especially in patients who may have a prolonged survival following pleurodesis. Despite significant advancements in the use of talc pleurodesis, several important gaps remain in the literature. Notably, there is a lack of comprehensive studies focusing on the efficacy and safety of large-particle (≥15 μm), asbestos-free talc. While this formulation has been associated with a reduced risk of complications such as acute respiratory distress syndrome (ARDS), most existing research has centered on smaller-particle talc or formulations with less stringent quality controls. Furthermore, the comparative effectiveness of talc slurry (TS) and talc insufflation (TI) using modern, large-particle, asbestos-free talc is underexplored. The absence of such data hinders the development of evidence-based guidelines for selecting the optimal delivery method for individual clinical scenarios While these advancements have improved the risk-benefit profile of talc pleurodesis, it is important to recognize that the procedure is not without risks. Thus, careful patient selection and monitoring remain essential to minimize complications 12. Reducing hospital stays and procedural morbidity is critical in improving patient outcomes, especially for individuals with malignant pleural effusion (MPE) or recurrent pneumothoraces. These conditions often affect patients with advanced malignancies or significant comorbidities, where maintaining quality of life is paramount. Shorter hospital stays and fewer complications directly enhance patients' overall well-being and comfort, particularly for those with limited life expectancy. Additionally, minimizing hospital stays alleviates the economic and logistical burdens on healthcare systems, promoting the broader implementation of pleurodesis as a sustainable intervention.
International guidelines, such as those issued by the British Thoracic Society (BTS), provide valuable insights into the current standards of care for pleurodesis. These guidelines recommend talc pleurodesis as a primary intervention for symptomatic management of recurrent pleural effusions and pneumothoraces when pleural drainage alone proves insufficient. Talc remains the preferred agent due to its high efficacy and relative safety profile. However, the BTS guidelines do not strongly favor one delivery method-talc slurry or talc insufflation-over the other, advocating instead for individualized approaches based on patient needs and resource availability. The guidelines emphasize the importance of using sterilized, asbestos-free, large-particle talc to reduce the risk of complications, including ARDS and long-term carcinogenic effects13.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
160 participants in 2 patient groups
Loading...
Central trial contact
Zeeshan Sarwar
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal